Kinnate Biopharma Sells Pan-RAF Inhibitor to Pierre Fabre Medicament

by Warren Seah

Kinnate Biopharma, a clinical-stage precision oncology company, has recently finalized a deal with Pierre Fabre Medicament, a global oncology company. The sale includes the company’s investigational pan-RAF inhibitor, exarafenib, and other pan-RAF program assets.

Strategic Move for Kinnate Biopharma

The sale of global rights to Pierre Fabre Laboratories marks a strategic shift for Kinnate Biopharma, aligning with their exploration of strategic alternatives. This move signifies a significant milestone in the company’s journey.

Terms of the Agreement

As per the agreement, Pierre Fabre Laboratories will acquire exarafenib and other pan-RAF assets, taking over 100% of the ongoing program and associated costs. In return, Kinnate will receive a total consideration of up to $31 million. This includes a $500,000 payment upon closing and a $30.5 million payment, contingent upon specific milestones being reached.

Seamless Transition

Unlike many acquisitions, this transaction has swiftly closed without any additional conditions. The immediate completion ensures a seamless transition of assets from Kinnate to Pierre Fabre Laboratories.

This strategic maneuver showcases the dynamic landscape of precision oncology and sets the stage for future collaborations within the industry.

You may also like

Leave a Comment